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Objective: To study the expression of microRNA-130b (miR-130b) in children acute
promyelocytic leukemia (APL) and its role for regulating PTEN expression.
Methods: A total of 50 children APL marrow tissues and 15 normal marrow tissues
between January and December in 2012 were collected into our study. The expression of
miR-130b in APL and normal marrow tissues were detected by quantitative real-time
polymerase chain reaction. MiR-130b inhibitor was transfected into HL-60 cells. Cell
Counting Kit-8 assay and ﬂow cytometry were used to measure cell proliferation and
apoptosis, respectively. The expression of PTEN, a potential target of miR-130b, and its
downstream genes, Bcl-2 and Bax, in transformed cells were detected by quantitative real-
time polymerase chain reaction and western-blot.
Results: The expression of miR-130b was signiﬁcantly higher in children APL marrow
tissues than in normal marrow tissues (P < 0.05). Down-regulation of miR-130b could
signiﬁcantly suppress cell proliferation and induce apoptosis in HL-60 cells (P < 0.05).
PTEN expression was upregulated when miR-130b was knocking-down (P < 0.05). As
downstream genes of PTEN, the expression of Bcl-2 and Bax were regulated as well.
Conclusions: MiR-130b is overexpressed in children APL marrow tissues and associ-
ated with cell growth. MiR-130b may promote children APL progression by inducing cell
proliferation and inhibiting apoptosis.1. Introduction
Acute promyelocytic leukemia (APL), classiﬁed as M3 in
French–American–British classiﬁcation systems, is a subtype of
acute myelocytic leukemia (AML). Globally, APL occupies
7%–27% of all AML types, while in China, this proportion
enlarges to 12%–23% [1]. Compared to other AML types, APL
has a higher risk of hemorrhage and causes a high mortality [2].
Nowadays, systematical chemotherapies based on all-trans-
retinoic acid (ATRA) and arsenic trioxide is the major treat-
ment method [3]. However, both single and combination drug
therapies have many disadvantages such as early drug
resistance, early recurrence, and serious side-effect [4]. Thus,
the treatment outcome and prognosis of APL are still
unsatisﬁed. Hence, the discovery of novel biologicaltherapeutic target is a key for improving the survival of APL
patients.
MicroRNAs (miRs) are small (19–25 nt), noncoding RNA
molecules that negatively regulate gene expression by interact-
ing with the 30 untranslated region of targeting mRNA, even-
tually leading to translational suppression and/or degradation of
the targeting mRNA [5,6]. In adult AML patients, the aberrant
expression of miR-335 was associated with chemoresistance
[7]. In children APL, miR-125b could inhibit cell apoptosis and
induce ATRA chemoresistance by targeting BCL2-antagonist/
killer 1 [8]. MiR-130b was demonstrated as an important onco-
genic miR in many cancers [9]. For example, in hepatocellular
carcinoma, miR-130b was up-regulated and associated with
large tumor metastasis [10]. It might be suggested that PTEN, a
classical tumor suppressor, was a target of miR-130b by bioin-
formatics study. As a member of phosphatases, PTNE can
change PIP3 into PIP2 by phosphorylation, consequently
inhibiting the activation of Akt signal [11].
In this study, the expression of miR-130b in children APL
marrow tissues was detected and its functions and mechanisms
for cell growth in vitro were investigated. Finally, we proved
that miR-130b was up-regulated in APL marrow tissues andunder the CC BY-NC-ND license
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apoptosis by inhibiting PTEN expression.
2. Materials and methods
2.1. Clinical specimens and cell culture
A total of 50 children APL marrow tissues and 15 normal
marrow tissues were collected and stored in liquid nitrogen
between January and December in 2012. The range of age was
from 7 to 14 year, and the median age was 9 year. The human
APL cell line, HL-60, was purchased from T Institute of
Biochemistry and Cell Biology, Chinese Academy of Sciences
(Shanghai, China). Cells were cultured in Gibco® RPMI 1640
medium (Gibco, USA) supplemented with 10% v/v fetal bovine
serum (FBS; Gibco, USA) and maintained in a humidiﬁed
incubator.
2.2. Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was isolated from marrow tissues and HL-
60 cells using TRIZOL® reagent (Invitrogen, USA). The relative
expression of miR-130b was detected by Bulge-Loop™ miR
qRT-PCR Starter Kit (RiboBio, Guangzhou, China). PTEN, Bcl-
2 and Bax mRNA expression levels were measured by Quant
one step qRT-PCR Kit (TIANGEN, Beijing, China). MiR-130b
primers were purchased from RiboBio Co., Ltd. PTEN, Bcl-2,
Bax and b-actin qPCR primers were synthesized by Augct Co.,
Ltd and the sequences were shown as follow: PTEN sense 50-
GTAAGGACCAGAGACAAAAAG-30, anti-sense 50-CTTTT
TTAGCATCTTGTTCTG-30, Bcl-2 sense 50- TTCTTTGAGT
TCGGTGGGGTC-30, anti-sense 50-TGCATATTTGTTTGGGG
CAGG-30, Bax sense 50- TCCACCAAGAAGCTGAGCGAG-
30, anti-sense 50-GTCCAGCCCATGATGGTTCT-30, b-actin 50-
CTCCATCCTGGCCTCGCTGT-30, anti-sense 50-GCTGTC
ACCTTCACCGTTCC-30. The 2−DDCT method was used for
data calculation.
2.3. MiR transfection
HL-60 cell transfection was performed using the Lipofect-
amine® 2000 Transfection Reagent (Invitrogen, USA) ac-
cording to the manufacturer instructions. Brieﬂy, 5 × 105 cells
were cultured in six-well culture plates containing 1.5 mL
RPMI 1640 per well without FBS. The 100 pmoL miR-130b
inhibitor or scrambled-miR inhibitor (RiboBio, Guangzhou,
China) was mixed with 5 mL Lipofectamine® 2000 in 500 mL
Opti-MEM® I Reduced Serum Medium (Gibco, USA) and
incubated for 15 min at room temperature. The complex was
then added to the cells and ensured full distribution over all
plate surface. After 8 h of incubation, the FBS and antibiotics
were added and the cells were incubated for the 24 h, 48 h and
72 h.
2.4. Cell Counting Kit-8 (CCK-8) assay
The viability of cells was assessed by the CCK-8. CCK-8
assay was performed at time intervals 24 h, 48 h and 72 h post
transfection. A total of 10 mL CCK-8 solution was added to
5 × 105 HL-60 cells suspended in 100 mL RPMI 1640 mediumand incubated for 4 h at 37 C in dark. Absorbance was
measured by using a spectrophotometer at 450 nm.
2.5. Flow cytometry (FCM) analysis
HL-60 cells were collected and diluted into 5 × 105 at time
interval 48 h post transfection. Cell cycles and the apoptotic cells
were evaluated by Annexin V-FITC and propidium iodine
staining (Roche, USA) according to the manufacturer's instruc-
tion and analyzed with a FCM.
2.6. Western blot
Cells were washed with cold PBS for twice and broken by
RIPA. Lysate was centrifuged at 15000 r/min for 15 min. The
supernatant was obtained and detected the protein content via
BCA Kit (Millipore, USA). Proteins were separated by vertical
electrophoresis and transferred to PVDF membrane (Millipore,
USA). PTEN, Bcl-2, Bax and b-actin antibodies (all purchased
from Santa Cruz, USA) were used to detect the proteins
expression, respectively. Secondary HRP-conjugated goat anti-
rabbit or anti-mouse antibody (Abgent, USA) were used at a
1:5000 dilution and developed by the ECL Regent (Millipore,
USA).
2.7. Statistical analysis
Measurement date were presented as mean ± SD. The SPSS
version 13.0 (SPSS, Chicago, USA) was used for two-tailed
Student-t test and ANOVA. P < 0.05 was considered statisti-
cally signiﬁcant.
3. Results
3.1. MiR-130b expression in APL marrow tissues
Analysis of qRT-PCR data demonstrated that the relative
expression of miR-130b was signiﬁcantly increased in APL
marrow tissues (n = 50, 2.198 ± 0.051) compared to normal
marrow tissues (n = 15, 6.562 ± 0.271) (P < 0.001).
3.2. Down-regulation effect of miR-130b inhibitor on
miR-130b expression in HL-60 cells
In order to elucidate the biological signiﬁcance of miR-130b,
negative control miR inhibitor (NC inhibitor, n = 8, 1.000) or
miR-130b inhibitor (n = 8, 0.331 ± 0.016) was transfected into
HL-60 cells. After 48 h post-transfection, miR-130b was
signiﬁcantly down-regulated in HL-60 cells (P < 0.001).
3.3. Effects of inhibition of miR-130b on suppressing
viability and inducing apoptosis of HL-60 cells
Overexpression of miR-130b could effectively inhibit
viability of HL-60 cells compared to control group (P < 0.01).
Moreover, BrdU incubation assay showed that miR-130b could
signiﬁcantly repress DNA synthesis of HL-60 cells
(135.37 ± 6.43 vs. 57.39 ± 4.20, P = 0.002). FCM tested the
inﬂuence of miR-130b for cell apoptosis. Compared to NC miR
group, miR-130b could effectively increase apoptotic cell per-
centage (13.352 ± 1.981 vs. 24.482 ± 1.943, P = 0.003).
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To investigate the possible molecular mechanisms, the
mRNA level of PTEN, a possible target of miR-130b, predicted
by bioinformatics retrieval, in APL marrow tissues, was ﬁrstly
detected, and Person correlation test was used to analyze the
association between miR-130b and PTEN mRNA. It could be
seen clearly that a negative correlation existed between miR-
130b and BMI-1 mRNA (r = −0.571, P < 0.001). Moreover, it
was also conﬁrmed that the expression of PTEN were up-
regulated in miR-130b inhibitor group than in NC group
(P < 0.001). As downstream genes of PTEN, the expression of
Bcl-2 and Bax were also regulated (P < 0.001). Expression of
Bcl-2 was decreased, and the expression of Bax was increased
(P < 0.001).
4. Discussion
APL is a special subtype of AML. High risk of bleeding and
DIC after chemotherapy by anthracyclines are the main features
of APL. Identiﬁcation of PML/RARa fusion gene promoted the
application of ATRA and arsenic trioxide [12]. APL became the
ﬁrst human cancer which could be treated with its tumor speciﬁc
antigen [13]. However, novel and safe therapeutic molecules are
still needed to be found to further improve patients' survival.
As a novel and effect therapeutic targets, miRs can play
double-edged sword roles in cancer, and their aberrant expres-
sions are related to many malignant features [14]. MiR-92a was
reported to suppress cell growth of HL-60 cells by silencing P63
expression [15,16]. MiR-21 is a famous onco-miR, and down-
regulating miR-21 could enhance HL-60 cell apoptosis induced
by cytarabine [17]. MiR-130b was reckoned as a prognostic
evaluation biomarker and a vital tumor promoter in many can-
cers. In ESCC, high expression of miR-130b was associated
with higher TNM stage and poorer prognosis, moreover, miR-
130b enhanced proliferation, migration, and invasion in human
ESCC cells by targeting PTEN [18].
In our study, it was found that the expression of miR-130b in
APL marrow tissues was signiﬁcantly higher than in normal
marrow tissues. That meant this differential expression of miR-
130b in APL marrow tissues might play an important regulation
function for APL progression. In vitro, the proliferation inhib-
iting effect was detected after knocking down miR-130b
expression, and cell apoptosis was also induced by miR-130b
inhibitor.
PTEN is located at 10q23.3 and encodes a dual-speciﬁcity
phosphatase with lipid and protein phosphatase activities [19].
PTEN dephosphorylates is an important activator of Akt
named PI(3,4,5)P3, which controls cell proliferation,
apoptosis, and many other functions [20]. Inhibition of PTEN
results in increased levels of activated p-Akt and consequently
regulates Bcl-2/Bax expression [21]. Studies indicated that
PTEN is a potential target of miR-221/222, miR-22 and miR-
144 in different malignancies [18]. In this study, it was
demonstrated that PTEN was a direct target of miR-130b by
qRT-PCR and western blot, thus promoting Bcl-2 expression
and reducing Bax expression. This phenomenon may partly
explain the effect of miR-130b for HL-60 cells proliferation and
apoptosis.
The results of our study indicate that expression of miR-130b
is up-regulated in patients with diagnosed APL. To the best ofour knowledge, this is an interesting study to demonstrate that
miR-130b is a tumor promoter by directly targeting PTEN in
APL.
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